Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 127   

Articles published

ABT 38.43 -0.17 (-0.44%)
price chart
Stocks to Watch: Abbott Labs, Bank of America, Yahoo
Among the companies with shares expected to actively trade in Wednesday's session are Abbott Laboratories, Bank of America Corp.
Abbott Laboratories profit beats forecast, but sales lag  Reuters
Abbott Laboratories (ABT): Stock With Unusual Social Activity
Related articles »  
Critical Alerts For Bank of America, Pandora Media, Oracle, Abbott ...
Today's PriceWatch Alerts cover the following stocks: Bank of America (NYSE:BAC) , Pandora Media (NYSE:P) , Oracle (NYSE:ORCL) , Abbott Laboratories (NYSE:ABT) , and CA Technologies (NASDAQ:CA) . InvestorsObserver's PriceWatch Alerts contain ...
Related articles »  
Glenmark to pay up to $25 million in damages to Abbott Labs
Mumbai: Glenmark Pharmaceuticals Ltd has to pay damages of up to $25 million to Abbott Laboratories after losing a patent infringement case related to the launch of its version of anti-hypertension drug Tarka.
Healthcare Watch List: Arena Pharmaceuticals (NASDAQ:ARNA), Abbott ...  Tech News
Zacks Reiterates Neutral Rating for Abbott Laboratories (ABT)  Ticker Report
Related articles »  
Expect Abbott To Raise Its 2014 Outlook Soon
Abbott has been one of the most successful companies for more than 125 years. Let's examine its most recent quarterly results.
Abbott's CEO Discusses Q1 2014 Results - Earnings Call Transcript
Good morning and thank you for standing by. Welcome to Abbott's First Quarter 2014 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call.
Related articles »  
Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT). In the report, Morgan Stanley noted, �The most challenging quarter of the year is behind ...
Related articles »  
Abbott Laboratories Enters Oversold Territory (ABT)
In trading on Thursday, shares of Abbott Laboratories Abbott Laboratories (NYSE: ABT) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $37.13 per share.
Related articles »  
Abbott Labs Progresses with Absorb
Abbott Laboratories (ABT - Analyst Report) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device.
Will Abbott Labs (ABT) Disappoint This Quarter?
Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie (ABBV - Analyst Report) in Jan 2013.
Related articles »  
Abbott Laboratories: This Company Has Potential To Expand Into Emerging ...
Equity researchers Jefferies Group, recently reiterated their buy rating for Abbott Laboratories' (ABT) stock. The stock is currently trading between $38-38.50 and the researchers have set a $45 price target.